Collaborative Practice, INR 4.9, and Vaccines Without a Prescription

Only if the collaborative practice agreement and protocol actually cover this patient and this drug - and then the pharmacist must follow the protocol exactly.

• Pennsylvania permits pharmacist-physician collaborative practice for drug therapy management when there is a valid written agreement. The pharmacist's authority is limited to the conditions, drugs, and parameters in that agreement; the pharmacist may not independently diagnose or prescribe outside it.
• The pharmacist should confirm that the patient was referred by a participating physician, that warfarin management is within the agreement, and that no protocol exclusion applies (for example, active bleeding, recent surgery, or a new interacting drug).
• An INR of 4.9 without bleeding fits the protocol's 4.5–5.0 range. The pharmacist may hold one dose, reduce the weekly dose by 10%, schedule a recheck in 72 hours, and notify the prescriber within 24 hours, documenting all of it.
• If the patient had bleeding, the pharmacist should arrange emergency evaluation rather than manage solely by protocol.
• If any element is missing, the pharmacist must contact the prescriber and may not adjust the dose independently.

Yes, for an adult, if the pharmacist is acting under a valid protocol or standing order and meets the practice requirements.

• Pennsylvania pharmacists may administer vaccines to adults under a protocol or standing order without an individual prescription. The pharmacist must screen for contraindications and precautions, obtain consent, provide the required vaccine information statements, and use proper technique and storage.
• The pharmacist must be trained in immunization and anaphylaxis management, have epinephrine available, and follow the protocol for emergency response.
• Documentation should include the vaccine, lot, site, date, administering pharmacist, and patient consent, and the information should be reported to the patient's primary care provider or the state immunization registry.
• If the patient does not know his primary care provider, the pharmacist should still document and give the patient a record to share. The absence of a named provider does not by itself prohibit administration, but the pharmacist should ask about allergies, immunosuppression, and prior reactions.

The agreement must be written, signed, specific, and subject to physician oversight.

• It should identify the parties, the conditions and drugs covered, the monitoring parameters and decision rules, the documentation required, the method and frequency of communication with the physician, and the physician review process.
• It should address patient consent, record retention, termination, and how urgent findings are handled. The pharmacist's authority is limited to what the agreement and protocol authorize.
• The agreement cannot expand the pharmacist's scope beyond Pennsylvania law. The pharmacist may not independently diagnose, initiate therapy outside the protocol, or manage a patient who has not been referred as the agreement requires.
• The agreement and related records should be maintained and available for inspection by the Board. If the agreement is ambiguous or expired, the pharmacist should not act under it.